– Completion of alternative public offering in which Pieris AG becomes a wholly-owned subsidiary of Pieris Pharmaceuticals, Inc. Freising, Germany – Pieris Pharmaceuticals, Inc. (OTC:PIRS) (formerly Marika, Inc.), a Nevada corporation, announced today its successful completion of a…
– recAP shown to improve skeletal and dental mineralisation in potentially new indication with high unmet medical need. Bunnik, The Netherlands - AM?Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory…
– Utrecht, The Netherlands and Copenhagen, Denmark - Ascendis Pharma A/S, a biopharmaceutical company that applies its innovative TransCon technology to address significant unmet medical needs, today announced the successful completion of a $60 million Series D financing. New investors…
– Trade sale marks success of portfolio company in Digital Health, an emerging theme in healthcare Utrecht, The Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the transatlantic growth capital firm specialized in the healthcare sector, today announced it has agreed to…
– Utrecht, the Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the transatlantic growth capital firm specialized in the healthcare sector, announces that its portfolio company Acacia Pharma (Cambridge, UK) announces positive Phase 3 results with APD421 for the management…
– Sandwich, UK – Levicept Ltd., a biopharmaceutical company focused on the development of LEVI-04, a p75 neurotrophin receptor fusion protein (p75NTR-Fc) for chronic pain indications, announces that it has closed a £10 million Series A financing with Advent Life Sciences, Gilde Healthcare…
– Utrecht, the Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the transatlantic growth capital firm specialized in the healthcare sector, announces that its portfolio company ProQR Therapeutics priced its initial public offering of 7,500,000 ordinary shares at an initial…
– Bunnik, The Netherlands - AM?Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces that it has closed a €12.2 million financing round led by Gilde Healthcare. Existing investors…
– Triggers milestone payment from Mylan OXFORD, UK – Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces that its Marketing Authorisation Application (MAA) for PSX1001 has been validated and is being…
– Sapiens acquired by Medtronic for $200 million in cash Utrecht, The Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the transatlantic growth capital firm specialized in the healthcare sector, today announces it has sold its stake in Sapiens Steering Brain Stimulation…
– COPENHAGEN, Denmark 7 - Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that its collaborative partner, Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, Merck Serono has initiated two new clinical studies…
– Utrecht (the Netherlands) / Cambridge (USA) — Gilde Healthcare, the transatlantic growth capital firm specialized in the healthcare sector, announces it has sold its minority stake in biopharmaceutical company Santaris Pharma A/S (Copenhagen, Denmark) to Roche (SIX: RO, ROG; OTCQX:…
– Strategic alliance to provide services from virology assay development and testing to formulation of accelerated clinical development plans for drugs, biologicals, vaccines and diagnostics Parsippany, New Jersey, United States and Rotterdam, the Netherlands – d3 Medicine LLC, an…
– Definiens AG, a Munich, Germany-based provider of a tissue diagnostics platform aimed at helping physicians improve treatment announced that it has closed a round of financing for € 15 Million. The round was co-led by new investor Wellington Partners and existing investor Gilde Healthcare…
– New Manufacturing Capabilities to Support early Development Mads Laustsen, formerly of CMC Biologics, Joins Symphogen 1 June 2014 COPENHAGEN, Denmark: Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today announced…
– SAN DIEGO (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the initiation of a Phase 2b clinical trial of its lead drug candidate, emricasan,…
– IRVINE, CA and AMSTERDAM – Agendia today announced a new agreement with Daiichi Sankyo regarding oncology drug development and personalized medicine. The agreement calls for Agendia’s oncology biomarker technology to be used in the assessment of novel pharmaceuticals now being researched…
– OXFORD, UK, and PITTSBURGH – Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, today announced that it has entered into a global licensing agreement with Mylan Inc. (Nasdaq: MYL), one of the world’s leading…
– EXETER, New Hampshire - Vapotherm, Inc. announced a $24MM financing round led by Gilde Healthcare. Adage Capital Management joined as new co-investor. The round was completed by existing investors Morgenthaler Ventures, Kaiser Permanente, 3x5 Special Opportunity Fund, Integral Capital…
– SAN DIEGO (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the initiation of a Phase 2 clinical trial of its lead drug candidate, emricasan,…
– Symphogen, A/S, a private biopharmaceutical company developing recombinant monoclonal antibody (mAb) mixtures for the treatment of cancer has signed a manufacturing agreement with Gallus BioPharmaceuticals, LLC (Gallus), a premier pure-play biologics contract manufacturing organization…
– Amsterdam, The Netherlands – uniQure, a Gilde Healthcare portfolio company, announced the pricing of its initial public offering of 5,400,000 ordinary shares at an initial public offering price of $17.00 per ordinary share raising $91.8 million and started trading under the symbol…
– MUNICH - Definiens, the global leader in image analysis for digital pathology and diagnostics announced today the signing of an agreement with Clarient Diagnostic Services, Inc.- which extends the use of Definiens’ automated image analysis software and solutions in Clarient's validated…
– Leveraging Orphan Drug Designation in Clinical Trial for Liver Transplant Recipients SAN FRANCISCO - (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease,…
– UTRECHT, THE NETHERLANDS – Gilde Healthcare Services has acquired a majority share in Viroclinics Biosciences (Viroclinics) a virology contract research organization, from Erasmus University Medical Center (Erasmus MC). The partnership between Viroclinics and Gilde Healthcare will…